Pharming reports favourable conclusion from first investigator-initiated direct comparative real-world study of acute hereditary angioedema therapies
Today Pharming acknowledged presentation of the results from an investigator-initiated comparative study of therapies in acute attacks of hereditary angioedema (“HAE”).
The study examined and compared re-dosing rates inter alia for human C1 esterase inhibitor in recombinant form (Ruconest®) and plasma-derived forms (Berinert®, Cinryze®) to icatibant (Firazyr®) in seven individual patients at risk of HAE attacks. A total of 69 attacks were recorded. The study was led by Professor Dr Marcus Magerl of the Department of Dermatology and Allergy at the Charité Universitätsmedizin Berlin, Berlin, Germany.
“This was a well-run independent investigator-led comparative study under real world conditions, which gives a clear signal confirming reports from patients.”- Dr Bruno Giannetti, Pharming’s COO